Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Mar;9(2):109-14.
doi: 10.1007/s11912-007-0006-3.

Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification

Affiliations
Review

Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification

Antonello Di Paolo et al. Curr Oncol Rep. 2007 Mar.

Abstract

Distribution of antineoplastic agents within tumors remains one of the major challenges in cancer chemotherapy because distribution is hampered by several factors related to the drug (its physicochemical characteristics) and to the neoplastic tissue (blood and lymphatic vasculature, cell density, extracellular matrix composition, and interstitium). The inhomogeneous distribution and structure of tumor vasculature lead to large avascular and hypoxic areas with low pH and high interstitial oncotic pressure. In these critical conditions, the gradient of drug concentrations from the vessels to the inner parts of the tumor is not sufficient to promote diffusion of pharmacologic agents. Again, cellular sequestration and binding to extracellular matrix represent further factors that limit drug distribution and reduce tumor sensitivity to chemotherapy. Several strategies have been investigated to circumvent drug resistance. The evaluation of liposomal and nanoparticle formulations and the characterization of newer bioreductive agents and drugs that should normalize tumor vasculature are in progress.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Future Oncol. 2005 Dec;1(6):779-86 - PubMed
    1. Nat Rev Cancer. 2004 Jul;4(7):528-39 - PubMed
    1. J Clin Oncol. 2001 Jan 15;19(2):535-42 - PubMed
    1. Cancer Res. 2006 Jan 15;66(2):1033-9 - PubMed
    1. Annu Rev Pharmacol Toxicol. 2006;46:381-410 - PubMed

Substances